Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 9, 2023 /PRNewswire/ -- Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet...

Click to view original post